Home LiteratureArticle Details
PMID: 21156277 Published · ppublish English Comment Journal Article

New antibody to stop tumor angiogenesis and lymphatic spread by blocking receptor partnering.

Cancer cell ·Vol. 18 ·No. 6 ·2010-12-14 ·Pages 541-3

McDonald DM

Abstract

Tvorogov et al. (2010) describe in this issue of Cancer Cell an antibody that inhibits homodimerization of vascular endothelial growth factor receptor-3 (VEGFR-3) and its heterodimerization with VEGFR-2, but not ligand binding. The work provides mechanistic insights into receptor dimerization and an approach to suppress both angiogenesis and lymphangiogenesis.

Authors & Affiliations
1 authors, click to expand affiliations / ORCID
McDonald Donald M
UCSF Comprehensive Cancer Center, Cardiovascular Research Institute, Department of Anatomy, University of California, San Francisco, CA 94143, USA. donald.mcdonald@ucsf.edu
References (10)
10 references, click to expand
  1. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization.
    Cancer Cell. 2010 Dec 14;18(6):630-40 PMID: 21130043
  2. Cell signaling by receptor tyrosine kinases.
    Cell. 2010 Jun 25;141(7):1117-34 PMID: 20602996
  3. Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale.
    Trends Mol Med. 2010 Mar;16(3):122-32 PMID: 20189876
  4. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.
    Cancer Cell. 2009 Mar 3;15(3):220-31 PMID: 19249680
  5. Structure of a VEGF-VEGF receptor complex determined by electron microscopy.
    Nat Struct Mol Biol. 2007 Mar;14(3):249-50 PMID: 17293873
  6. Lymphangiogenesis: Molecular mechanisms and future promise.
    Cell. 2010 Feb 19;140(4):460-76 PMID: 20178740
  7. Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling.
    Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13252-7 PMID: 20616078
  8. Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization.
    Mol Cancer Ther. 2009 Jul;8(7):1885-92 PMID: 19584234
  9. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation.
    Nature. 2008 Jul 31;454(7204):656-60 PMID: 18594512
  10. Structural determinants of growth factor binding and specificity by VEGF receptor 2.
    Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2425-30 PMID: 20145116
Article Info
Journal
Cancer cell
Abbr.
Cancer Cell
ISSN
1878-3686
DOI
10.1016/j.ccr.2010.11.030
Email
donald.mcdonald@ucsf.edu
Published
2010-12-14
Pages
541-3
Language
English
Region
United States
NLM ID
101130617
PMCID
PMC3031147
Grants
NHLBI NIH HHS · P01 HL024136-31A1 · United States
NHLBI NIH HHS · P01 HL024136 · United States
NHLBI NIH HHS · R01 HL059157 · United States
NHLBI NIH HHS · R01 HL096511-01 · United States
NHLBI NIH HHS · R01 HL096511 · United States
NHLBI NIH HHS · R01 HL059157-13 · United States
Corrections
CommentOn
PMID: 21130043
External Links
PubMed source DOI: 10.1016/j.ccr.2010.11.030 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2